WIO 2021
SUMMER SYMPOSIUM
AUGUST 26–29
AMELIA ISLAND, FLORIDA

Supporters

WWW.WIOONLINE.ORG  @WIOONLINE  @WIO_WOMENINOPHT
Women in Ophthalmology (WIO) was founded to enhance and improve the professional environment for women ophthalmologists. WIO encourages diversity, impartiality, economic parity, and strives to cultivate new opportunities for leadership, education and public service in the field of ophthalmology for ourselves and future generations.

What started as a lunch meeting at the American Academy of Ophthalmology (AAO) has grown to an internationally recognized organization, an affiliate society of the AAO, which provides scientific/medical education and professional development resources for women in ophthalmology. WIO recognizes the many facets to being a female ophthalmologist and provides training, services and benefits to meet all of those needs.

Women in Ophthalmology
655 Beach Street
San Francisco, CA 94109
www.wioonline.org

WIO 2021 BOARD OF DIRECTORS

LISA NIJM, MD, JD
Chief Executive Officer

REGINE PAPPAS, MD
President

ERIN SHRIVER, MD, FACS
Past-President

SUSAN BURDEN, MD
President-Elect

GRACE SUN, MD
Vice President

PURNIMA PATEL, MD
Treasurer

SARA WESTER, MD
Secretary

CYNTHIA MATOSSIAN, MD
Development Director

WANDA MARTINEZ, MD
Membership Director

CAROL ZIEL, MD
AAO Councilor

FEMIDA, KHERANI, MD, FRCS
AAO Councilor Alternate

LEJLA VAJZOVIC
Director-at-Large

GLORIA FLEMING, MD
Director-at-Large

CHRISTINA WENG
Director-at-Large

KIMBERLY WINGES
Director-at-Large
We would like to thank our generous supporters of the 2021 Summer Symposium:

**DIAMOND SUPPORTERS**

**PLATINUM SUPPORTER**

**GOLD SUPPORTER**

**SILVER SUPPORTER**

**BRONZE SUPPORTERS**
Welcome to the Women in Ophthalmology Virtual Summer Symposium 2021!

What a year it has been! Following on the heels of success of our first ever virtual symposium, WIO has evolved yet again to bring you a unique, dual-track hybrid meeting. We are excited to welcome all of you both in person and at home! This incredible program (really two meetings in one) has been designed with curated content to offer you the best of the best topics for women in ophthalmology. We are thrilled to welcome you back with numerous opportunities to learn first-hand from some of the most outstanding leaders in our field, rejuvenate from a challenging year, and grow with new friendships.

We are deeply grateful to the leveled sponsors and exhibitors listed in this book. They have come together once again to support Women in Ophthalmology in great ways. We would not be able to bring you such a robust meeting and all of our leadership development programs without their generous contributions. These industry leaders recognize the importance of our mission and have committed to helping us achieve our goals as women ophthalmologists.

Please join us in visiting the exhibit hall (both virtually and in person) and participating in the interactive networking events. We want to thank our sponsors for their generous support. This is a wonderful opportunity to connect, network, learn of new opportunities to work together and identify partners in industry to help us deliver the highest quality ophthalmic care for our patients.

We hope you have an incredible meeting filled with exciting new knowledge, skills, opportunities, and great friendships!

Sincerely,

Lisa M. Nijm, MD, JD
CEO, Women in Ophthalmology
WIO Clinical Trials Training Program

We are excited to announce the continuation of the Women in Ophthalmology Clinical Trials Training Program with the aim to increase the number of women ophthalmologists in research. Our 2020–2021 program was a huge success, with several virtual trainings offered throughout the year. We are pleased to announce that this program will continue, with the 2021-2022 program launching at this Summer Symposium, and Clinical Trials trainings being scheduled through the Summer Symposium next year.

The rationale behind this program is twofold:

1. Diversity amongst clinical trial investigators fosters participation of diverse study patient populations.

2. There is a paucity of female lead investigators in ophthalmology.

If, as a profession, we truly want to increase diversity in leadership, research is the ideal venue to move the needle. Clinical trial involvement creates an abundance of leadership opportunities with the ability to author scientific publications, present findings at major meetings, and participate in advisory boards.

As we have evaluated topics presented at our annual WIO Summer Symposium, we learned that many female ophthalmologists had an interest in being involved in clinical research but would like further education in understanding how to initiate a clinical trial, recruit patients, handle an audit, manage budget shortfalls, etc.

CLINICAL TRIALS PROGRAM SURVEY

To clearly define educational gaps and provide meaningful educational content, we launched a Clinical Trials Program Survey to the WIO community. The results of this survey aided in structuring a comprehensive training and mentorship program for our members.

Join us for the Clinical Trials Training Program Networking Reception on Friday, August 27th at 5:00 p.m. This will be an exclusive networking mixer for physicians and medical affairs personnel, and all are welcome! The companies listed below have committed to this one-of-a-kind educational program to empower women ophthalmologists in clinical trials research. Please join us in thanking them for their efforts.
Hotel Map

- **Ritz Carlton Ballroom:**
  - General Session
  - Gala Dinner

- **Talbot A-C:**
  - Skill Labs

- **Talbot D-E:**
  - Exhibits

- **Talbot F-H:**
  - Skill Labs

- **Talbot Foyer:**
  - Posters

- **Kings Bay:**
  - Registration

- **Oceanfront Lawn:**
  - Welcome Reception

- **Courtyard Lawn:**
  - Clinical Trials Reception
  - Closing Reception

- **Amelia & The Colonnade:**
  - Live Well

- **Santa Maria 1 & 2:**
  - Breakouts

- **Plaza 1 & 2:**
  - Breakouts
Dine Around Networking

Local Restaurants

These are some great spots for local dining and cocktails on Amelia Island and historic downtown Fernandina Beach.

Bob’s Steak & Chop House
80 Amelia Village Circle
Closed Sunday & Monday
(904) 432-2201
www.bobs-steakandchop.com

Dinner at Bob’s isn’t just a meal, it’s an experience with a lively atmosphere and simple elegance. Bob’s offers prime steaks, chops and seafood served by a friendly and knowledgeable staff. At Bob’s, dinner comes with your choice of potato and our iconic glazed carrot, giving you a great value. Once you experience Bob’s special brand of service and food, it won’t be long until you’re a regular.

Brett’s Waterway Café
1 South Front Street
(904) 261-2660

Dine on creative land or sea dishes served in a casual dining atmosphere. Enjoy the view as you overlook the Fernandina Harbor and marina on the Amelia River. Open for lunch and dinner. Featuring a full bar and extensive wine list.

Burlingame Restaurant
20 S. 5th Street
Closed Sunday
(904) 432-7671
www.burlingamerestaurant.com

Chef Chad’s cuisine is seasonally inspired, modern American food with a twist. He wants our guests to find new excitement in classic dishes and go to great lengths to deliver with every plate. The made-from-scratch menu is small by design to focus on a handful of exquisite dishes each season. This same made-from-scratch ethic shines through in our craft cocktail offerings.

Ciao Italian Eatery
614 Centre Street
(904) 206-4311
www.ciaoitalianeatery.net

In an upscale yet casual, modern setting, wonderful ambiance assures your perfect evening.

Join us for dinner or light fare, from our exceptional ultra-thin crust pizza, appetizers, pasta, seafood, and entrees. There is a beautiful full bar, hand crafted cocktails, extensive wine list and Peroni on tap.

Cucina South
4828 1st Coast Hwy #1
Closed Monday
(904) 432-7920
www.cucinasouth.com

An Italian Bistro featuring pasta, pizza, seafood, and wine. “Years of experience culminated with a passion for food, wine and love for people!”

David’s Restaurant
802 Ash Street
Closed Tuesday
(904) 310-6049
www.amelaislanddavids.com

David’s is a premier and authentic Steak House & Seafood Restaurant that has been proudly serving Amelia Island area and beyond since 2012. Since then, our mission has been to provide high-quality food for all those that wish to combine an intimate and relaxed ambiance with skillful cooking into one extraordinary dining experience.

España
22 S. 4th Street
(904) 261-7700
www.espanadowntown.net

Specializing in traditional flavors from Spain & Portugal. Choose to dine in our cozy main dining room, enclosed patio dining room or in our lush outdoor garden.

Joe’s 2nd Street Bistro
14 S. 2nd Street
(904) 321-2558
www.joesbistro.com

Located in a restored 1900s home in downtown Fernandina Beach, Florida, Joe’s 2nd Street Bistro features fresh, local seafood, certified angus beef and a unique wine list to fit all occasions. Open since 1998, Joe’s has become a mainstay in Fernandina’s historic district.

Lagniappe (“lan-yap”)  
4810 First Coast Hwy
(904) 844-2634
www.lagniappeamelia.com

Inspired by the culture and flavors of New Orleans, Charleston and Savannah, Lagniappe Restaurant combines the traditions of the French Creole with unique twists on Southern culinary staples using only the freshest local ingredients.

LeClos
20 S. 2nd Street
Closed Sunday & Monday
(904) 261-8100
www.leclos.com

Located in Fernandina’s Historic District since 1996, Le Clos serves delicious Provencal dishes by candlelight in a charming, intimate 1906 cottage. The menu items at Le Clos are prepared carefully and presented beautifully with an emphasis on local fresh seafood. The eclectic wine list offers the perfect accompaniment for every menu selection.

Pogo’s Kitchen
1408 Lewis Street
Closed Monday
(904) 432-8483
www.pogoskitchen.com

It isn’t enough to step away from the everyday hustle. You need a place to go, a restaurant built to replenish. Step into southern refinement with a bend, visit us on Amelia Island at POGO’s Kitchen. A bright, breezed eatery tucked away from the main lines, waiting to unpack your day and refill your glass.
# Live Program Schedule

*times listed in Eastern Daylight Time*

## THURSDAY, AUGUST 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 PM – 4:30 PM</td>
<td>Charity Golf Tournament (separate registration required)</td>
<td>Golf Club</td>
</tr>
<tr>
<td>3:00 PM – 7:30 PM</td>
<td>Registration Open</td>
<td>Kings Bay</td>
</tr>
<tr>
<td>5:00 PM – 6:00 PM</td>
<td>Eye Sip, You Sip, We all Sip Together - Let’s Mingle!</td>
<td>Salon Terrace</td>
</tr>
<tr>
<td>6:00 PM – 6:30 PM</td>
<td>WIO Welcome / Opening Session / Meeting Kick-off</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Regine Pappas, MD, WIO President</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lisa Nijm, MD, JD, WIO Chief Executive Officer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refocusing the Gender Lens: Letting your Credibility and Confidence Shine Through</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tori Arens, Vice President, Drug Product Manufacturing, Aerie Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>6:30 PM – 7:30 PM</td>
<td>Dinner + CME Spotlight</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Innovative Treatment Protocols that can Redefine the Management of nAMD and DR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Judy E. Kim, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sophie Bakri, MD</td>
<td></td>
</tr>
<tr>
<td>7:45 PM – 9:00 PM</td>
<td>Opening Reception / Champagne Social</td>
<td>Ocean Front Lawn</td>
</tr>
</tbody>
</table>

## FRIDAY, AUGUST 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 AM – 5:30 PM</td>
<td>Registration Open</td>
<td>Kings Bay</td>
</tr>
<tr>
<td>6:00 AM – 7:00 AM</td>
<td>Live Well: Yoga and Mindfulness</td>
<td>Amelia</td>
</tr>
<tr>
<td></td>
<td>Instructor: Priya Mathews, MD, MPH</td>
<td></td>
</tr>
<tr>
<td>6:45 AM – 8:00 AM</td>
<td>Breakfast + CME Spotlight (6:45 AM – 7:00 AM check-in)</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Presbyopia: Emerging Treatments Offer New Hope For the Aging Eye</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Lisa Nijm, MD, JD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jennifer Loh, MD</td>
<td></td>
</tr>
<tr>
<td>8:05 AM – 8:10 AM</td>
<td>Welcome</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Jesse Berry, MD, WIO Program Committee Chair</td>
<td></td>
</tr>
<tr>
<td>8:10 AM – 9:10 AM</td>
<td>Keynote Session: Breaking the Glass Ceiling in Ophthalmology</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Moderator: Erin Shriver, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Journey to the C-Suite: Navigating a Career in a Male Dominated Industry</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeannette Bankes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Audience Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>9:10 AM – 10:10 AM</td>
<td>Panel Discussion: Hot Topics - Clinical and Therapeutic Innovations</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Moderators: Jaya Kumar, MD, and Roni Levin, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New Retina Surgical Techniques</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lejla Vajzovic, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research Innovations in Retina</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Christine Kay, MD</td>
<td></td>
</tr>
</tbody>
</table>
Live Program Schedule

*times listed in Eastern Daylight Time

FRIDAY, AUGUST 27

New Surgery Approaches in Pediatric Ophthalmology
Janet Alexander, MD

New Oculoplastics Surgical Techniques
Cat Burkat, MD, FACS, and Andrea Kossler, MD

New Techniques and Considerations for Cataract Surgery
Priyanka Sood, MD

New Therapeutic Options for Presbyopia
Jennifer Loh, MD

Therapeutic Innovations in Neuro-Ophthalmology
Kimberly Winges, MD

10:10 AM – 10:45 AM
Break with Exhibitors
Talbot D-E

10:45 AM – 11:15 AM
Poster Session I
Talbot Foyer

11:15 AM – 11:55 AM
Bernice Z. Brown Memorial Lecture & Award
Ritz-Carlton Ballroom
Introduction: Lisa Nijm, MD, JD
From Bench to Boardroom: Navigating the Business World in Ophthalmology
Awardee: Adrienne Graves, PhD

11:55 AM – 12:15 PM
Life Hack Video Presentations & Award
Ritz-Carlton Ballroom
Moderator: Angeline Nguyen, MD

12:15 PM – 1:30 PM
Lunch + CME Spotlight (12:15 PM – 12:30 PM check-in)
Ritz-Carlton Ballroom
Mitigating Thyroid Eye Disease through Prompt Diagnosis and Treatment
Chair: Sara Wester, MD, FACS
Andrea Kossler, MD, FACS

1:30 PM – 2:30 PM
Break with Exhibitors
Talbot D-E

1:30 PM – 3:00 PM
Skill Labs (separate registration required)
Moderators: Cynthia Matossian, MD, and Priyanka Sood, MD

• Dry Eye Wetlab
Talbot F-H
Moderators: Cynthia Matossian, MD, and Priyanka Sood, MD

• Glaucoma – MIGS, SHUNTS, Oh My!
Talbot A-C
Moderators: Lauren Blieden, MD, Carla Bourne, MD

Instructors: Larissa Camejo, MD, Jiaxi Ding, MD, Shelly Jain, MD, and Thasarat Vajaranant, MD

3:00 PM – 4:00 PM
Pelvic Health Smarts for Your Lady Parts
Ritz-Carlton Ballroom
Moderator: Carla Bourne, MD
Lynn Deang, PT, DPT, Cert MDT, PRPC

4:00 PM – 5:00 PM
Pool Networking
Pool Cabanas
Exhibitor Raffle Winners Announced

4:00 PM – 5:30PM
Live Well: Watercolor Painting Class (separate registration required)
Talbot Colonnade
Barbara Arnold, MD

5:00 PM – 6:00 PM
WIO Clinical Trials Training Program Networking Reception
Courtyard Lawn

6:00 pm – 9:00 PM
Expand Your Network: Dine Around (Dinner on Your Own)
# Live Program Schedule

*times listed in Eastern Daylight Time

## SATURDAY, AUGUST 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 AM - 5:30 PM</td>
<td>Registration Open</td>
<td></td>
</tr>
<tr>
<td>6:00 AM - 6:30 AM</td>
<td><strong>Live Well – Setting Your Intentions for the Day / Mindfulness</strong>&lt;br&gt;Kara Pepper, MD</td>
<td></td>
</tr>
<tr>
<td>6:00 AM - 7:00 AM</td>
<td><strong>Live Well – Water Aerobics</strong>&lt;br&gt;Richard Zak, MD</td>
<td>Indoor Pool</td>
</tr>
<tr>
<td>6:45 AM - 7:45 AM</td>
<td><strong>Live Well – Turtle Walk</strong>&lt;br&gt;(separate registration required)</td>
<td>Hotel Lobby</td>
</tr>
<tr>
<td>7:00 AM - 8:00 AM</td>
<td><strong>Breakfast with Exhibitors</strong></td>
<td>Talbot D-E</td>
</tr>
<tr>
<td>8:00 AM - 8:40 AM</td>
<td><strong>WIO Honorary Lecture &amp; Award</strong>&lt;br&gt;Introduction: Regine Pappas, MD&lt;br&gt;The Last Quarter: Growing by Giving&lt;br&gt;Awardee: Leslie Jones, MD&lt;br&gt;Audience Q &amp; A</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td>8:40 AM - 9:10 AM</td>
<td><strong>Panel: Reset the Rules - Mastering Contract Negotiations in Ophthalmology</strong>&lt;br&gt;Lisa Nijm, MD, JD&lt;br&gt;Jeanette Bankes, Yolande Barnard, R.V. Paul Chan, MD, Erin Powers, MBA, and Nancy Sabin</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td>9:10 AM - 12:10 PM</td>
<td><strong>Breakout Sessions</strong>&lt;br&gt;(25-minute sessions with one rotation)&lt;br&gt;• Building Your Niche in Academic Medicine&lt;br&gt;  Moderators: Maria Aaron, MD, Caroline Bauman, MD, and Fasika Woreta, MD, MPH&lt;br&gt;• Medical Student &amp; Resident Session&lt;br&gt;  Moderator: Moran (Roni) Levin, MD&lt;br&gt;  Katrina Chin Loy, MD, Janice Law, MD, and Grace Sun, MD&lt;br&gt;• Working on Your Side Hustles&lt;br&gt;  Moderator: Alejandra de Alba Campomanes, MD, MPH&lt;br&gt;• Rising to the Next Level: Becoming A Thought Leader in Ophthalmology&lt;br&gt;  Moderator: Lisa Nijm, MD, JD&lt;br&gt;  Kathryn Colby, MD, Kate Kline, Andrea Kossler, MD, and James O’Connor&lt;br&gt;• The Pros and Cons of Non-Traditional Jobs in Ophthalmology&lt;br&gt;  Moderator: Adrienne Graves, PhD&lt;br&gt;• A Guide to Starting Your Own Practice&lt;br&gt;  Moderator: Katerina Kurteeva, MD&lt;br&gt;• URM Mentoring Session&lt;br&gt;  Moderators: Usiwo Abugo, MD and Gloria Fleming, MD</td>
<td>Santa Maria 2, Santa Maria 1, Plaza 1, Plaza 2, Plaza 2, Ballroom Foyer, Ritz-Carlton Ballroom</td>
</tr>
</tbody>
</table>
Live Program Schedule
*times listed in Eastern Daylight Time

SATURDAY, AUGUST 28

12:10 PM – 12:30 PM  **Break with Exhibitors**  Talbot D-E
12:15 PM – 1:30 PM  **Lunch + CME Spotlight** (12:15 PM – 12:30 PM check-in)  Ritz-Carlton Ballroom
   - Futuristic Approaches that Reduce Treatment Burden in Age-related Macular Degeneration and Diabetic Macular Edema
   - Chair: Caroline Baumal, MD
   - Christina Weng, MD, MBA
1:30 PM – 2:30 PM  **Break with Exhibitors**  Talbot D-E
1:30 PM – 3:30 PM  **Skill Labs**
   - Basic Phacoemulsification Lab  Talbot A-C
     - Moderators: Vandana Reddy, MD, and Fasika Woreta, MD
     - Instructors: Zaina Al-Mohtaseb, MD, Jella An, MD, MBA, Shelly Jain, MD, and Priya Mathews, MD
   - Strabismus: Basic and Advanced Techniques  Talbot F-H
     - Moderators: Sudha Nallasamy, MD, and Yi Ning Strube, MD, MS, FRCSC, DABO
     - Instructors: Alejandra de Alba Campomanes, MD, MPH, Laura Enyedi, MD, and Lisa Thompson, MD
3:30 PM – 4:30 PM  **Live Well – How to Solve Any Problem**  Amelia
   - Instructor: Kara Pepper, MD  Hotel Lobby
4:00 PM – 5:00 PM  **Pool Networking**  Pool Cabanas
   - Exhibitor Raffle Winners Announced
5:30 PM – 6:30 PM  **Sponsor / Exhibitor Networking Event** (By Invitation Only)  Talbot Colonnade
6:30 PM – 7:30 PM  **Cocktail Hour with Group Photo**  Courtyard Lawn
7:30 PM – 9:00 PM  **Awards Gala Dinner & WIO's Got Talent**  Ritz-Carlton Ballroom
9:00 PM – 11:00 PM  **Get Up and Dance!**  Ritz-Carlton Ballroom

SUNDAY, AUGUST 29

5:30 AM – 11:30 AM  Registration Open  Kings Bay
6:30 AM – 8:00 AM  **Breakfast with the Experts**  Ritz-Carlton Ballroom
6:45 AM – 7:45 AM  **Live Well – Turtle Walk** (separate registration required)
8:00 AM – 8:45 AM  **Oculoplastics: Injections & Techniques – Live Demo**  Ritz-Carlton Ballroom
   - Instructor: Keshini Parbhu, MD
8:45 AM – 9:30 AM  **Workshop: Professional Communication in Texting Age & Virtual Environment**  Ritz-Carlton Ballroom
   - Marshelia DeVan, MBA
9:30 AM – 9:45 AM  **Updates in International Ophthalmology**  Ritz-Carlton Ballroom
   - Moderator: Sara Wester, MD, FACS
   - Christine Nelson, MD
9:45 AM – 10:00 AM  **New President, New Congress, New Tax Law Updates**  Ritz-Carlton Ballroom
   - Carole Foos, CPA
## Live Program Schedule

*times listed in Eastern Daylight Time*

### SUNDAY, AUGUST 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM – 10:15 AM</td>
<td>Update on Advocacy &amp; Surgical Scope Battles</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Ninita Brown, MD</td>
<td></td>
</tr>
<tr>
<td>10:15 AM – 10:45 AM</td>
<td>Best Research Abstract Presentations &amp; Joanne Angle Award</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Moderators: Usiwoma Abugo, MD, and Lauren Dalvin, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Retinal Neuroaxonal Loss is Associated with Progressive Regional Brain Atrophy and Disability in Multiple Sclerosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Heba Altarawneh, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Split-face Comparison Between Onabotulinumtoxin A and Prabotulinumtoxin A in Treatment of Glabellar Frown Lines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Preeya Mehta, BA</td>
<td></td>
</tr>
<tr>
<td>10:45 AM – 11:15 AM</td>
<td>Surgical Video Roundtable</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Moderator: Andrea Kossler, MD</td>
<td></td>
</tr>
<tr>
<td>11:15 AM – 11:30 AM</td>
<td>Meeting Wrap-Up</td>
<td>Ritz-Carlton Ballroom</td>
</tr>
<tr>
<td></td>
<td>Invitation to 2022 WIO Summer Symposium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Usiwoma Abugo, MD, Lisa Nijm, MD, JD, and Regine Pappas, MD</td>
<td></td>
</tr>
</tbody>
</table>
Virtual Program Schedule
*times listed in Eastern Daylight Time

THURSDAY, AUGUST 26

6:00 PM – 6:30 PM  Welcome to WIO 2021 Virtual LIVE STREAM
Regine Pappas, MD, WIO President
Lisa Nijm, MD, JD, WIO Chief Executive Officer
Refocusing the Gender Lens: Letting your Credibility and Confidence Shine Through
Tori Arens, Vice President, Drug Product Manufacturing, Aerie Pharmaceuticals

6:30 PM – 7:30 PM  CME Spotlight LIVE STREAM
Innovative Treatment Protocols that can Redefine the Management of nAMD and DR
Chair: Judy E. Kim, MD
Sophie Bakri, MD

FRIDAY, AUGUST 27

7:00 AM – 8:00 AM  CME Spotlight
Presbyopia: Emerging Treatments Offer New Hope For the Aging Eye
Chair: Lisa Nijm, MD, JD
Jennifer Loh, MD

8:05 AM – 8:10 AM  Welcome
Jesse Berry, MD, WIO Program Committee Chair

8:10 AM – 9:10 AM  Keynote Session: Breaking the Glass Ceiling in Ophthalmology LIVE STREAM
Moderator: Erin Shriver, MD
Journey to the C-Suite: Navigating a Career in a Male Dominated Industry
Jeannette Bankes
Audience Q & A
Under the Glass Ceiling: Where We Are and What We Have to Do
Audina Berrocal, MD
Audience Q & A

9:10 AM – 10:10 AM  Panel Discussion: Hot Topics - Clinical and Therapeutic Innovations LIVE STREAM
Moderators: Jaya Kumar, MD, and Roni Levin, MD
New Retina Surgical Techniques
Lejla Vajzovic, MD
Research Innovations in Retina
Christine Kay, MD
New Surgery Approaches in Pediatric Ophthalmology
Janet Alexander, MD
New Oculoplastics Surgical Techniques
Cat Burkat, MD, FACS, and Andrea Kossler, MD
New Techniques and Considerations for Cataract Surgery
Priyanka Sood, MD
New Therapeutic Options for Presbyopia
Jennifer Loh, MD
# Virtual Program Schedule

*times listed in Eastern Daylight Time

## FRIDAY, AUGUST 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 AM – 10:40 AM</td>
<td><strong>Poster Viewing</strong> (on your own)</td>
<td></td>
</tr>
<tr>
<td>10:40 AM – 11:15 AM</td>
<td><strong>Visit the Virtual Exhibit Hall - Thank Our Sponsors!</strong></td>
<td></td>
</tr>
<tr>
<td>11:15 AM – 11:55 AM</td>
<td><strong>Bernice Z. Brown Memorial Lecture &amp; Award</strong> <strong>LIVE STREAM</strong></td>
<td><strong>Introduction:</strong> Lisa Nijm, MD, JD&lt;br&gt;<strong>Awardee:</strong> Adrienne Graves, PhD&lt;br&gt;<strong>Audience Q &amp; A</strong></td>
</tr>
<tr>
<td>11:55 AM – 12:15 PM</td>
<td><strong>Life Hack Video Presentations &amp; Award</strong> <strong>LIVE STREAM</strong></td>
<td><strong>Moderator:</strong> Angeline Nguyen, MD</td>
</tr>
<tr>
<td>12:15 AM – 12:30 AM</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>12:30 PM – 1:30 PM</td>
<td><strong>CME Spotlight</strong> <strong>LIVE STREAM</strong></td>
<td><strong>Mitigating Thyroid Eye Disease through Prompt Diagnosis and Treatment</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Sara Wester, MD, FACS&lt;br&gt;<strong>Andrea Kossler, MD, FACS</strong></td>
<td></td>
</tr>
<tr>
<td>1:30 PM – 2:30 PM</td>
<td><strong>Hot Topics &amp; Innovations</strong> <strong>VIRTUAL ONLY</strong></td>
<td><strong>Moderator:</strong> Sahar Bedrood, MD, PhD&lt;br&gt;<strong>Innovations in Uveitis:</strong>&lt;br&gt;Olivia Lee, MD&lt;br&gt;<strong>Updates in IOL Selection for Refractive Cataract Surgery:</strong>&lt;br&gt;Neda Shamie, MD&lt;br&gt;<strong>Ocular Oncology Updates - Choroidal Nevus and Melanoma: Smart Imaging:</strong>&lt;br&gt;Carol Shields, MD&lt;br&gt;<strong>Glaucoma Updates:</strong>&lt;br&gt;Janey Wiggs, MD&lt;br&gt;<strong>Audience Q &amp; A</strong></td>
</tr>
<tr>
<td>2:30 PM – 3:00 PM</td>
<td><strong>Visit the Virtual Exhibit Hall - Thank Our Sponsors!</strong></td>
<td></td>
</tr>
<tr>
<td>3:00 PM – 4:00 PM</td>
<td><strong>Building Grit: Managing Your Reaction to Surgical Complications</strong> <strong>VIRTUAL ONLY</strong></td>
<td><strong>Moderator:</strong> Tova Mannis, MD&lt;br&gt;<strong>Tom Oetting, MD, Mark Mannis, MD, FACS, and Nandini Gandhi, MD</strong></td>
</tr>
</tbody>
</table>

## SATURDAY, AUGUST 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 8:40 AM</td>
<td><strong>WIO Honorary Lecture &amp; Award</strong> <strong>LIVE STREAM</strong></td>
<td><strong>Introduction:</strong> Regine Pappas, MD&lt;br&gt;<strong>The Last Quarter: Growing by Giving</strong>&lt;br&gt;<strong>Awardee:</strong> Leslie Jones, MD&lt;br&gt;<strong>Audience Q &amp; A</strong></td>
</tr>
</tbody>
</table>
# Virtual Program Schedule

*times listed in Eastern Daylight Time

## SATURDAY, AUGUST 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:40 AM – 9:10 AM</td>
<td><strong>Panel: Reset the Rules - Mastering Contract Negotiations in Ophthalmology</strong></td>
<td>Live Stream</td>
</tr>
<tr>
<td></td>
<td>Lisa Nijm, MD, JD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeanette Bankes, Yolande Barnard, R.V. Paul Chan, MD, Erin Powers, MBA,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and Nancy Sabin</td>
<td></td>
</tr>
<tr>
<td>9:10 AM – 9:40 AM</td>
<td><strong>Poster Viewing</strong> (on your own)</td>
<td></td>
</tr>
<tr>
<td>9:40 AM – 10:10 AM</td>
<td><strong>Visit the Virtual Exhibit Hall - Thank Our Sponsors!</strong></td>
<td></td>
</tr>
<tr>
<td>10:10 AM – 11:00 AM</td>
<td><strong>Panel: Diversity, Equity, and Inclusion in Ophthalmology</strong></td>
<td>Live Stream</td>
</tr>
<tr>
<td></td>
<td>Moderator: Janice Law, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ninita Brown, MD, PhD, R.V. Paul Chan, MD, and Leslie Jones, MD</td>
<td></td>
</tr>
<tr>
<td>11:00 AM – 11:30 AM</td>
<td><strong>Bausch +Lomb Symposium: Innovations in Inflammation and IOP Control</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reena Garg, MD, and Cynthia Matossian, MD, FACS</td>
<td></td>
</tr>
<tr>
<td>11:30 AM – 12:30 PM</td>
<td><strong>Join an On-Demand Wellness/Fitness Class</strong> (on your own)</td>
<td></td>
</tr>
<tr>
<td>12:30 PM – 1:30 PM</td>
<td><strong>CME Spotlight</strong> (live stream)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Futuristic Approaches that Reduce Treatment Burden in Age-related</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Macular Degeneration and Diabetic Macular Edema</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Caroline Baumal, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Christina Weng, MD, MBA</td>
<td></td>
</tr>
<tr>
<td>1:30 PM – 2:30 PM</td>
<td><strong>Building Grit: Changing the Paradigm from Bossy to Baller</strong></td>
<td>Virtual Only</td>
</tr>
<tr>
<td></td>
<td>Moderator: Lindsay Rhodes, MD, MSPH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bossy to Baller: My Top Tips</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emily Chew, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bossy to Baller: My Top Tips</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Julia Haller, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Audience Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>2:30 PM – 3:30 PM</td>
<td><strong>Reproductive Options for Ophthalmologists 101</strong></td>
<td>Virtual Only</td>
</tr>
<tr>
<td></td>
<td>Moderators: Audina Berrocal, MD, and Aleksandra Rachitskaya, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lana Srur, MD</td>
<td></td>
</tr>
<tr>
<td>3:30 PM – 4:45 PM</td>
<td><strong>Building Inner Resources to Flourish in Medicine</strong></td>
<td>Virtual Only</td>
</tr>
<tr>
<td></td>
<td>Agnes Wong, MD, PhD, FRCSC</td>
<td></td>
</tr>
<tr>
<td>4:45 PM – 8:00 PM</td>
<td><strong>View On-Demand Bonus Content</strong> (on your own)</td>
<td></td>
</tr>
<tr>
<td>8:00 PM – 9:00 PM</td>
<td><strong>Awards Gala &amp; WIO’s Got Talent</strong> (live stream)</td>
<td></td>
</tr>
</tbody>
</table>

## SUNDAY, AUGUST 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM – 8:45 AM</td>
<td><strong>Oculoplastics: Injections &amp; Techniques – Live Demo</strong></td>
</tr>
<tr>
<td></td>
<td>Instructor: Keshini Parbhu, MD</td>
</tr>
<tr>
<td>8:45 AM – 9:30 AM</td>
<td><strong>Workshop: Professional Communication in Texting Age &amp; Virtual Environment</strong></td>
</tr>
<tr>
<td></td>
<td>Marshela DeVan, MBA</td>
</tr>
<tr>
<td>9:30 AM – 9:45 AM</td>
<td><strong>Updates in International Ophthalmology</strong></td>
</tr>
<tr>
<td></td>
<td>Moderator: Sara Wester, MD, FACS</td>
</tr>
<tr>
<td></td>
<td>Christine Nelson, MD</td>
</tr>
</tbody>
</table>
## Virtual Program Schedule

*times listed in Eastern Daylight Time*

### SUNDAY, AUGUST 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 AM – 10:00 AM</td>
<td><strong>New President, New Congress, New Tax Law Updates</strong> LIVE STREAM</td>
<td>Carol Foos, CPA</td>
</tr>
<tr>
<td>10:00 AM – 10:15 AM</td>
<td><strong>Update on Advocacy &amp; Surgical Scope Battles</strong> LIVE STREAM</td>
<td>Ninita Brown, MD</td>
</tr>
<tr>
<td>10:15 AM – 10:45 AM</td>
<td><strong>Best Research Abstract Presentations &amp; Joanne Angle Award</strong> LIVE STREAM</td>
<td>Moderators: Usiwoma Abugo, MD, and Lauren Dalvin, MD</td>
</tr>
<tr>
<td></td>
<td>Retinal Neuroaxonal Loss is Associated with Progressive Regional Brain Atrophy and Disability in Multiple Sclerosis</td>
<td>Heba Altarawneh, MD</td>
</tr>
<tr>
<td></td>
<td>A Split-face Comparison Between Onabotulinumtoxin A and Prabotulinumtoxin A in Treatment of Glabellar Frown Lines</td>
<td>Preeya Mehta, BA</td>
</tr>
<tr>
<td></td>
<td>Epidemiology of Giant Cell Arteritis in the United States: A Nationwide Study From 2007–2016</td>
<td>Karen Qiang, BS</td>
</tr>
<tr>
<td>10:45 AM – 11:15 AM</td>
<td><strong>Surgical Video Roundtable</strong> LIVE STREAM</td>
<td>Moderator: Andrea Kossler, MD</td>
</tr>
<tr>
<td>11:15 AM – 11:30 AM</td>
<td><strong>Meeting Wrap-Up</strong> LIVE STREAM</td>
<td>Invitation to 2022 WIO Summer Symposium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Usiwoma Abugo, MD, Lisa Nijm, MD, JD, and Regine Pappas, MD</td>
</tr>
</tbody>
</table>
On-Demand Virtual Content

**POSTERS ABSTRACTS**

From rare cases to innovative research to impactful quality improvement, WIOS posters have it all. Learn from your colleagues and applaud the exciting work being done by the WIO in our on-demand poster session.

**SURGICAL VIDEOS**

WIOS surgical prowess is unlimited. From IOLs to baerveldts to foreign bodies, the surgical video section has it all.

**“LIFE HACK” VIDEOS**

As busy career women, WIO is all about supporting and enhancing productivity in and out of work. Our life hacks section is just that—the very best tips and tricks from your colleagues. You’ll want to watch them all!

**OMIC: DOCUMENTATION STRATEGIES TO MANAGE RISK**

Laura Fine, MD and Michelle Pineda, MBA

The importance of documentation is underscored in this OMIC Risk Management course. Using actual OMIC closed claims, we hope to illustrate where the lack of documentation or incomplete documentation negatively impacted the defense of the claim. Recommendations on documentation are also provided to mitigate future liability risk. WIO Members who attend this risk management session can earn a 10% discount on their OMIC insurance premium.

**Objectives:**

- Identify the role of documentation plays in patient safety and defense of medical malpractice claims.
- Identify the elements of documentation in diagnostic/preoperative care, informed consent, inter-operative and post-operative care.
- Identify risk management resources available to prevent patient harm and mitigate medical malpractice claims.

**LIVE WELL – WELLNESS WORKOUTS**

Allison Early, MD

Join us for a series of hand-picked workouts over the course of the weekend to keep your mind and body in tune! We have created a schedule of on-demand workout classes including some favorite Peloton rides, stretches, run/walks, meditations, and even some yoga classes that are available to all on YouTube. Take part at the scheduled time to join along with other WIOs, or complete the suggested courses on your own time for a little refresh whenever you need it!

**LIVE WELL - CULINARY SKILL LABS**

- **Cocktails** – Audina Berrocal, MD
  
  BARrocal! Join me to prepare one of my favorite cocktails! At the end of a hard week at work, there is nothing better than sharing a cocktail with your significant other. It is the perfect time to decompress and share the trials and tribulations of our lives! I will show you how to make a simple yet flavorful cocktail!

- **Charcuterie Board** – Regine Pappas, MD
  
  Making a charcuterie board is a perfect way to keep your guests entertained and awed with the presentation and variety of appetizers while waiting for the main meal. Learn how to WOW your guests with a perfect board for any occasion.

- **Meal Prep & Dinner** – Shanika Esparaz, MD
  
  Who loves to meal prep? Join Dr. Shanika Esparaz, mother of two toddler girls and married to a physician as well, as she talks about her meal prep tips and tricks. No equipment needed for this video, just sit back, relax, and enjoy a surgeon mom’s version of the cooking channel. We will be making a lunch dish (toddler friendly), a dinner the whole family can enjoy, as well as a filling protein snack!
Skill Lab Sponsors

GLAUCOMA – MIGS, SHUNTS, OH MY!

- Allergan
- GLAUKOS
- IVANTIS
- New World Medical
- Sight Sciences

DRY EYE WETLAB

- Alcon
- Bruder
- Johnson & Johnson Vision
- Kala Pharmaceuticals
- Lumenis
- Quidel
- Sight Sciences
- Tarsus
- TearLab
Skill Lab Sponsors

BASIC PHACOEMULSIFICATION LAB

Alcon
SEE BRILLIANTLY

BAUSCH+LOMB

Johnson & Johnson VISION

ZEISS

STRABISMUS: BASIC AND ADVANCED TECHNIQUES

BAUSCH+LOMB
Special Recognitions

OPENING RECEPTION & CHAMPAGNE SOCIAL

Aerie Pharmaceuticals is the exclusive sponsor of our Opening Reception & Champagne Social, which will kick-off our meeting in a fabulous way, bringing the WIO community together. Tune in for a presentation from Tori Arens, Aerie’s VP of Drug Product Manufacturing. She’ll be speaking on Refocusing the Gender Lens: Letting your Credibility and Confidence Shine Through.

SATURDAY GALA BANQUET & WIO’S GOT TALENT

Horizon Therapeutics is the exclusive sponsor of our Saturday evening Gala Banquet and “WIO’s Got Talent” Competition. The evening will be an entertaining and collaborative experience for all, live and virtual attendees alike!

VIRTUAL SESSION SPONSOR

Bausch + Lomb is sponsoring an educational virtual session on Friday at 11:00 a.m. EDT in our virtual platform. The session is titled Innovations in Inflammation and IOP Control and their speakers are Reena A. Garg, MD, and Cynthia Matossian, MD, FACS.
Special Recognitions

**BERNICE Z. BROWN MEMORIAL LECTURE AND AWARD**

WIO’s annual Bernice Z. Brown Memorial Lecture and Award has been generously sponsored this year by **EyePoint Pharmaceuticals**. WIO is grateful to EyePoint for their continued support of WIO.

**OMIC SESSION AND WIO MEMBER DISCOUNT**

Thank you **OMIC** for sponsoring our risk-management session: Documentation Strategies to Manage Risk. WIO members who attend this session (on-demand in the virtual platform) will be eligible for 10% off their OMIC insurance premium. Be sure to sign in to earn credit.

**RESIDENT TRAVEL AWARDS**

**Healio** has generously contributed toward the WIO Resident Travel Awards this year, making it possible for three resident attendees to attend the Summer Symposium. WIO is grateful for this support.
Special Recognitions

**LEADERSHIP DEVELOPMENT AND MENTOR SESSIONS**

Leadership development and mentoring are the highlights of the Summer Symposium. We are proud to have Santen sponsoring these “can’t miss” sessions this year.

**OFFICIAL WIFI SPONSOR**

We are excited to welcome Spark Therapeutics this year as WIO’s exclusive WiFi sponsor. Thank you, Spark, for bringing the internet and WIO’s virtual platform into the hands of our live attendees.

**OFFICIAL MEDIA PARTNERS**

WIO would like to thank Bryn Mawr Communications, Inc and Healio for being the official media sponsors of the 2021.
Exhibit Hall

Talbot D–E

PLAY THE EXHIBIT HALL BINGO RAFFLE!

1. Visit the exhibit hall.
2. Collect stamps on your card.
3. Return your stamped cards to the WIO Registration Desk on Friday and Saturday by 3:30pm to be entered in the raffles.

Great prizes have been donated and a drawing will take place at the Pool Networking Sessions on Friday and Saturday and at the Awards Gala on Saturday night.

---

B1  Aerie Pharmaceuticals
B2  Alcon
B3  Avellino Labs
B4  Ocular Therapeutix
B5  Novartis - Medical
B6  Novartis
B7  Regeneron
B8  RVL Pharmaceuticals
B9  Eyepoint Pharmaceuticals
B10 Johnson & Johnson

T1  Sight Sciences
T2  Dompe
T3  Tearlab Corporation
T4  Modernizing Medicine
T5  Lumenis
T6  Sun Ophthalmics
T7  Lensar
T8  Microsurgical Technology
T9  Zeiss
T10 Surgilum
T11 Oculus Surgical
T12 Tearlab Corporation
T13 Nanodropper
T14 Ivantis

T15  Staar
T16  Glaukos
T17  Phone COA
T18  Oyster Point
T19  Horizon Therapeutics
T20  Bruder Healthcare Company
T21  Bausch + Lomb
T22  Bausch + Lomb
T23  New World Medical
T24  AIS Healthcare Ophthalmics
T25  Kala Pharmaceuticals
T26  OMIC
T27  Axogen
T28 Twenty/Twenty Beauty

WWW.WIOONLINE.ORG  23  WIO 2021 SUPPORTERS BOOK
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Please visit www.aeriepharma.com.

AIS Healthcare Ophthalmics is a quality leader in custom medications for surgical and clinical care, including chronic dry eye therapy. From our easy and affordable serum tears (NovoTears) to our customized surgical combination drops (OPDrops), we offer more than 200 critical ophthalmic formulations, compounded in state-of-the-art facilities and with processes that exceed regulatory standards. By offering proactive patient engagement and comprehensive customer service for practices, we partner with prescribers to support patients with complex eye conditions, making days easier and lives better.

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at www.Allergan.com.
Supporter Directory

AVELLINO LABS
1505 Adams Dr, Ste B2
Menlo Park, CA 94025
(650) 396-3741
www.avellino.com

AvaGen is the first genetic eye test that confidently empowers eyecare professionals (ECPs) to protect and preserve vision by providing personalized genetic data that accurately quantifies the risk of keratoconus and the presence of visually significant corneal dystrophies. The genetic data Avagen provides adds a new and unique dimension to management and treatment decisions, by helping ECPs understanding the risk or presence of sight-threatening conditions early and accurately. It helps guide management and treatment decisions including sight-saving interventions and surgical decisions. With Avagen ECPs will know early, act personally, and decide confidently.

AXOGEN
13631 Progress Blvd, Ste 400
Alachua, FL 32615
(888) 296-4361
www.axogenicinc.com

Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers.

BAUSCH + LOMB
400 Somerset Corporate Blvd
Bridgewater, NJ 08807
(800) 553-5340
www.bausch.com

Bausch + Lomb is a global eye health organization with core businesses in over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry.

BRUDER HEALTHCARE COMPANY
1115 Ridgeland Pkwy #101
Alpharetta, GA 30004
(888) 827-8337
www.brudersx.com

Bruder Healthcare, a leader in the eye care industry recognized for the #1 Doctor Recommended Moist Heat Eye Compress, recently introduced a new practice essential: the Bruder Sx Pre-Surgical Patient Prep Kit. The easy-to-use kit includes Eyelid Cleansing Wipes, a pure hypochlorous acid Eyelid Solution, and an enhanced Pre-Surgical Compress—all housed in a practical case. Lid hygiene routines are commonly recommended for treatment of dry eye symptoms, but they’re especially important prior to ophthalmic surgery. Bruder products are designed to optimize the ocular surface and minimize the bacterial load on the lids. Available to recommend or stock.
Supporter Directory

BRYN MAWR COMMUNICATIONS (BMC)
1008 Upper Gulph Rd
Wayne, PA 19087
(484) 581-1800
www.bmctoday.com

BMC is a full-service communications company with a broad catalogue of multimedia properties serving numerous medical specialties and a growing range of strategic support services. BMC’s leading vision brands include Eyetube, Eyewire, CRSToday, MillennialEYE, Glaucoma Today, Retina Today, and Modern Optometry. As part of its growing portfolio of strategic services for the eye care community, BMC recently launched YoungMD Connect, a platform to empower the future leaders in ophthalmology. BMC also provides event management, medical writing services, expertise in social media influencer campaigns, and medical affairs support services.

DOMPÈ
181 Second Ave
Suite 600
San Mateo, CA 94401
(833) 366-7387
www.oxervate.com/hcp

Dompé is an Italian biopharmaceutical company based in Milan with US headquarters in the San Francisco Bay Area. It has a 100+ year legacy of medical innovation and is committed to seeking further advances that address unmet medical needs in the areas of ophthalmology, transplants, oncology and diabetes. This commitment to innovation has resulted in successful development collaborations with over 200 centers of excellence. Dompé’s commitment to ophthalmology includes the first topical biologic FDA-approved for an ophthalmic indication, and continued exploration of new indications through ongoing trials.

EYEPOINT PHARMACEUTICALS, INC.
480 Pleasant St, Ste B300
Watertown, MA 02472
(833) 393-7646
www.eyepointpharma.com

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.

EYES ARE THE STORY
C/o ESSIRI Labs
Boston, MA 02113
(617) 275-2417
www.eyesarethestory.com

Launched in 2020, Eyes Are The Story is a new bio-beauty brand developed by ESSIRI Labs in Boston. The women-led startup, founded by Amy Gallant Sullivan, is re-writing beauty through the lens of eye safety, mining a treasure trove of ocular surface science to bring eye-kind skincare and optocosmetics to clinics and consumers globally. Patients from across a spectrum of vision concerns, particularly dry eye disease and meibomian gland dysfunction, have praised the products for their performance and comfort, without having to sacrifice style. Eyes Are The Story is available online at eyesarethestory.com and in select clinics nationwide.
Supporter Directory

FRICKIN’ FABULOUS – COLOR STREET NAILS
(414) 614-0198
www.frickinfabulous.com

I love waiting for my nails to dry...said NO ONE EVER! Going to the nail salon can be fun, but who has the time? But having nice looking hands can make you feel so put together. Enter Color Street. Be frickin’ fabulous in no time flat with 100% real nail polish strips with no dry time, no smudges, and stays on like a salon manicure for 10-14 days. Remove with nail polish remover for no damage to your nails. For the gel and acrylic die-hards, Color Street can be put over those finishes as well. For those with many demands on their time Color Street is a great, flexible solution. Go from the office to an event with a matching manicure in minutes. Take some time for yourself and try these nail strips today!

GLAUKOS
229 Avenida Fabricante
San Clemente, CA 92672
(949) 367-9600
www.glaukos.com

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

HEALIO
6900 Grove Rd
Thorofare, NJ 08086
(856) 994-9900
www.healio.com/osn

Healio, the online home of Ocular Surgery News is bringing you highlights from the WIO Summer Symposium. Get daily news and perspective on the fully re-engineered Healio.com. The all-new Healio offers an enhanced user experience aimed at providing specialty health care professionals with personalized news and education. Visit Healio.com/Tour. Also, check out our line of ophthalmology journals, including OSLI Retina, offering scholarly science and expedited peer review.

HORIZON THERAPEUTICS
1 Horizon Wy
Deerfield, IL 60015
(855) 380-0472
www.horizontherapeutics.com

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.
IVANTIS, INC.
201 Technology Dr
Irvine, CA 92618
(949) 333-1332
www.ivantisinc.com

Ivantis Inc. developed the Hydrus® Microstent, the only minimally invasive microstent that dilates and scaffolds the primary outflow path of the eye through a Tri-Modal® mechanism of action. The device allows outflow of aqueous humor, dilates and scaffolds Schlemm’s canal and spans approximately 90 degrees to optimize access to the collector channels in the eye. It is one of the most rigorously researched and thoroughly studied MIGS devices, in patients with a wide range of disease severities. The Hydrus Microstent is indicated for use in conjunction with cataract surgery for adults with mild to moderate POAG. FDA approved Aug 2018.

JOHNSON & JOHNSON, INC.
1700 East St. Andrew Pl
Santa Ana, CA 92705
(714) 247-8200
www.jjvision.com

At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we’ve developed solutions for every stage of life—to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world’s leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere.

KALA PHARMACEUTICALS, INC.
490 Arsenal Wy
Watertown, MA 02472
(781) 996-5252
www.kalarx.com

Kala is a biopharmaceutical company focused on innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® Drug Delivery Technology to two ocular therapies, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%. The Company also has a pipeline of proprietary NCE development programs.

LEMONGRASS SPA WITH LINDSEY MEYER
3743 Gardenia Ave
Long Beach, CA 90807
(937) 381-9486
www.lemongrasswithlindsey.com

As an independent consultant with Lemongrass Spa Products for the past 4.5 years, I know what healthy and safe ingredients can do for your skin! Our products are handcrafted with ingredients that condition, soothe, and heal your skin. Fun fact: We keep our ingredients simple. If you take a look at our ingredient lists, you’ll know every word! We are gluten free, fragrance free, cruelty free, vegan, handcrafted, and made in the USA. Text the word “eye” to 937-381-9486 for a special on your first order.
LENSAR, INC.
2800 Discovery Dr
Orlando, FL 32826
(888) 536-7271
www.lensar.com

LENSAR®, the leader in next-generation femtosecond cataract laser technology, continues to focus on astigmatism with Streamline®. This latest advancement is dedicated to help surgeons confidently manage astigmatism and optimize outcomes, for both toric IOLs and arcuate incisions. Streamline’s IntelliAxis Refractive Capsulorhexis® steep axis capsulor markings guide precise and confident toric IOL alignment. Wireless transfer of preoperative data from multiple devices, iris registration and adaptive compensation for cyclotorsion further contribute to the system’s accuracy and enable seamless treatment planning. Building on the strength of LENSAR’s femtosecond cataract laser platform, Streamline is revolutionizing surgeons’ ability to deliver optimized outcomes for astigmatic patients.

Lumenis Vision, the proud inventor of Intense Pulsed Light, SLT and the first argon photocoagulator, is renowned for technological breakthroughs in ophthalmic, light-based devices with a long list of industry gold standards. With over 50 years of presence in the eye care industry, Lumenis Vision has focused on providing eye care providers with innovative therapies to preserve and improve the sight of patients worldwide.

Built by practicing ophthalmologists, the all-in-one ophthalmology-specific EHR system, EMA®, and suite of solutions, including Practice Management and patient engagement tools, can help save time and improve practice performance. The award-winning EMA EHR also caters to subspecialties such as cataract and refractive, glaucoma, retina, oculoplastics and pediatrics.

Monat is an anti-aging botanically based hair care, skin care and wellness company dedicated to helping people feel and look their most beautiful. We use exceptional ingredients from nature, sourced from around the globe, and we combine modern technology to produce safe, effective products which yield incredible results. Come join me and discover Monat!
Supporter Directory

**MONOCLE PETS FROM THE CARMEL ART LAB**
3373 NE 150th St
Lake Forest Park, WA 98155
(954) 854-3242
www.carmelartlab.com

Monocle Pets from the Carmel Art Lab was established in 2021 by pediatric ophthalmologist, Carmel Mercado MD. Carmel originally started drawing eyewear on animals to help her pediatric patients get comfortable with wearing glasses. Monocle Pets is an online store specializing in fun, ‘nerdy’, cheerful badge pins and art prints of animals in glasses. Carmel also hand paints custom portraits of pets in eyewear of the owner’s choice. Popular with both kids and kids-at-heart, our Monocle Pets designs make great gifts for children, clinic staff, and all ophthalmology boss babes with a soft spot for animals.

**MICROSURGICAL TECHNOLOGY**
8415 154th Ave NE
Redmond, WA 98052
(425) 556-0544
www.microsurgical.com

MST provides high-quality, innovative products for complex cataract and glaucoma surgeries. We proudly offer the Malyugin Ring, MST Instrumentation, MST Capsule Retractors, TrabEx, TrabEx+, Trabectome, Diamond Knives, Keratomes, Cannulas, Allegro Silicone I/A and more. MST is based in Redmond, WA and provides ophthalmic devices globally.

**NANODROPPER**
442 51st Ave NW
Rochester, MN 55901
(507) 405-5676
www.nanodropper.com/
conferences

Nanodropper offers value-based solutions to close health equity gaps while promoting patient education and advocacy. The Nanodropper adaptor is the only FDA-listed, volume-reducing adaptor for eyedrop bottles designed to deliver precisely the amount of fluid the eye can absorb. Smaller drops reduce the waste and cost of in-clinic and Rx formulations while minimizing local and systemic side effects. Nanodropper’s products and educational content help patients navigate issues like vision insurance, eye doctor appointments, and deploying their resources in an efficient way. These initiatives align with Nanodropper’s mission of helping patients take back control of their eye health.

**NEW WORLD MEDICAL**
10763 Edison Ct
Rancho Cucamonga, CA 91730
(909) 377-4205
www.newworldmedical.com

New World Medical’s mission is to preserve and enhance vision by delivering innovations to benefit humanity. New World Medical is committed and determined in leading the ophthalmic industry in the treatment of glaucoma and providing eye care professionals with the most advanced cutting-edge technologies in order to alleviate the suffering of glaucoma patients around the world. New World Medical’s flagship products include the Ahmed® Glaucoma Valve, Ahmed ClearPath®, Kahook Dual Blade®, and KDB GLIDE® available throughout the United States and international markets. New World Medical - Humanity’s vision is our focus.
Supporter Directory

NOVARTIS
One Health Pkz
East Hanover, NJ 07936
(862) 778-8000
www.novartis.com

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.

OCULAR THERAPEUTIX
24 Crosby Dr
Bedford, MA 01730
(781) 357-4000
www.ocutx.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of care by creating sustained release alternatives. It is our intention to develop a product portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing.

OCULUS SURGICAL, INC.
562 NW Mercantile Pl, Ste 104
Port Saint Lucie, FL 34986
(772) 236-2622
www.oculussurgical.com

25 years ago, OCULUS Optikgeräte GmbH, headquartered in Wetzlar, Germany, developed and launched the SDI®/BIOM® Wide-Angle Viewing System, which forever changed how retinal surgeons view vitreoretinal surgery. OCULUS Surgical, Inc. together with our parent company, OCULUS Optikgeräte GmbH, will continue to provide the ophthalmic surgical market with advancements in wide-angle viewing, as well as new, innovative tools for today’s ophthalmic surgeon.

OCUSOFT, INC.
30444 Southwest Fwy
Rosenberg, TX 77471
(800) 233-5469
www.ocusoft.com

Since 1986 OcuSOFT®, most recognized for its #1 Doctor Recommended Brand of Eyelid Cleansers, has served the ophthalmic community with a unique selection of proprietary brands including OcuSOFT® Lid Scrub® Eyelid Cleansers and OcuSOFT® Thermal 1-Touch® Localized Heat Therapy. Please visit our website to learn more!
Supporter Directory

**OJM GROUP**
8044 Montgomery Rd, Ste 440
Cincinnati, OH 45236
(877) 656-4362
www.ojmgroup.com

OJM Group is a multidisciplinary wealth management firm whose team members have worked with over 1,500 physicians nationwide to help them build wealth, reduce taxes and protect personal and corporate assets. OJM principals have co-authored more than a dozen books for physicians, including Wealth Planning for the Modern Physician and Wealth Management Made Simple. OJM will offer WIO attendees a free print copy or ebook download of these books, as well as a complimentary consultation.

**OMIC**
655 Beach St
San Francisco, CA 94109
(415) 771-1002
www.omic.com

OMIC is the largest insurer of ophthalmologists in America and the only carrier dedicated specifically to the specialty. Owned and operated by ophthalmologists, OMIC’s record of defending ophthalmic claims beats the performance of multispecialty carriers by a wide margin. Visit OMIC’s exhibit for information on rates, premium discounts and dividends.

**OYSTER POINT**
202 Carnegie Ctr, Ste 109
Princeton, NJ 08540
(609) 382-9032
www.oysterpointrx.com

Oyster Point Pharma is a clinical-stage biopharmaceutical company with a pharmaceutical nasal spray in development to treat the signs and symptoms of dry eye disease.

**PEERLESS MEDICAL, INC.**
1600 Technology Dr
O’Fallon, MO 63369
(636) 675-3319
www.straplessn95.com

The Strapless Mask is amazingly comfortable and lightweight, as there are no straps! It is cool and breathable and one of our greatest compliments is that your glasses/loupes fog up way less if not being completely eliminated! The Strapless Mask doesn’t itch and doesn’t move when you speak! As well, it offers complete-perimeter N95 protection and is American Made! Until now, N95’s, and all masks in general, were stuffy, warm and uncomfortable. Protection and comfort are now available together, in one mask!
Supporter Directory

**PHONE COA, LLC**
3213 Ladson Rd, Ste 1364
Ladson, SC 29456
(910) 667-2127
www.phonecoa.com

Whether your practice needs temporary technician support during a staffing shortage, or a longer-term partnership to manage the pre-loading needs of your clinics, our trained professionals serve as your virtual COA by pre-loading charts and pre-screening patients according to your needs. And the best part...the cost for a Phone COA is often cheaper than hiring a full-time technician, without the stress of finding, training, and retaining these highly qualified team members. Pre-Loading * Pre-Screening * Patient Education

---

**QUIDEL**
9975 Summers Ridge Rd
San Diego, CA 92121
(858) 874-1517
www.quideleyehealth.com

Quidel’s Eye Health solutions, InflammaDry and QuickVue, are point-of-care tests for the detection of ocular surface diseases. InflammaDry detects elevated levels of MMP-9 for dry eye. QuickVue diagnoses adenoviral conjunctivitis. Quidel now also offers COVID-19 testing solutions. With onsite testing, same day results and reporting, Quidel can help protect the health of your patients and staff. Quidel enhances the health of people around the globe with diagnostics that provide improved patient outcomes and healthcare system economic benefits.

---

**REGENERON**
777 Old Saw Mill River Rd
Tarrytown, NY 10591
(914) 847-7000
www.regeneron.com

For 30+ years, our mission has been to use the power of science to bring new medicines to patients. Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases.

---

**REGENXBIO INC.**
9600 Blackwell Rd, Ste 210
Rockville, MD 20850
(240) 552-8181
www.regenxbio.com

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. We have developed a broad pipeline of gene therapy programs using our NAV Technology Platform to address genetic diseases through two modalities: AAV-mediated antibody delivery and monogenic gene replacement. We believe this platform forms a strong foundation for our current programs and with our ongoing research and development, we expect to continue to expand the platform.
### Supporter Directory

**RISE BREWING CO.**  
(646) 400-0410  
[www.risebrewingco.com](http://www.risebrewingco.com)

We're on a mission to make the best tasting beverages on the planet, using the highest quality organic ingredients we can source. Organic doesn't just taste better – it’s better for you, for our planet, and for the future generations who depend on us. We believe that what you put in is what you get out. The clean taste of our organic ingredients shine through in our refreshingly smooth lineup of nitrogen infused nitro cold brew coffee, oat milk lattes and our dairy free oat milks.

---

**RVL PHARMACEUTICALS, INC.**  
400 Crossing Blvd  
Bridgewater, NJ 08807  
(908) 809-1300  
[www.upneeq.com](http://www.upneeq.com)

RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT), is solely dedicated to bringing Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% to market and enhancing patient care. Born out of the eye care community, Upneeq® is the first and only FDA-approved prescription treatment for acquired ptosis in adults, and represents a significant advancement for practitioners and their patients. Upneeq® is available exclusively through RVL's fully-owned and integrated pharmacy that was designed to modernize prescription access through a consistent and seamless experience from Rx to fulfillment for provider and patient.

---

**Santen, INC.**  
6401 Hollis St, #125  
Emeryville, CA 94608  
(415) 268-9100  
[www.santenusa.com](http://www.santenusa.com)

Santen is a global specialized company focused solely on ophthalmology. We’re committed to serving serious unmet needs by developing innovative solutions that protect and restore vision and, in turn, preserve quality of life for people around the world. Santen USA, is an important part of our ophthalmic research and development efforts worldwide and the home of our regional business teams. By leveraging our deep industry knowledge and a network of external partners, we aim to deliver novel therapies and make hope a reality for people facing vision impairment and loss.

---

**SIGHT SCIENCES**  
4040 Campbell Ave, Ste 100  
Menlo Park, CA 94025  
(877) 266-1144  
[www.sightsciences.com](http://www.sightsciences.com)

Sight Sciences is a growth-stage medical device company dedicated to the development of intelligently designed and engineered products that address the underlying physiology of ophthalmic diseases. The company’s portfolio consists of the OMNI® Surgical System which is a novel, implant-free device which can be used in combination with cataract surgery or as a standalone procedure, as well as the non-surgical TearCare® System which is a device that applies heat to the eyelids to remove blockage, the hallmark of MGD.
Supporter Directory

SPARK THERAPEUTICS
3737 Market St, Ste 1300
Philadelphia, PA 19104
(855) 772-7589
www.sparktx.com

At Spark Therapeutics, we are committed to developing potential gene therapies for serious genetic diseases and we strive to bring those investigational therapies to patients. Our founders included scientists and clinicians who devoted decades to the research of gene therapies with the goal of making these investigational, one-time treatments a reality. Spark Therapeutics is a member of the Roche Group.

STAAR SURGICAL
25651 Atlantic Ocean Dr
Lake Forest, CA 92630
(626) 303-7902
www.staar.com

STAAR designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision.

SUN OPHTHALMICS
2 Independence Wy
Princeton, NJ 08540
(609) 720-5305
www.sunophthalmics.com

Sun Ophthalmics is reenergizing eye care. We are a US division of Sun Pharma, a global specialty pharmaceutical corporation with operations in over 150 countries. Our mission is to launch innovative ophthalmic products that complement your approach to treatment. We focus on your unmet treatment needs in patient care so you can focus on your patients. Discover a brighter future in eye care.

SURGILUM
1717 Shipyard Blvd, Ste 140
Wilmington, NC 28403
(910) 202-2202
www.surgilum.com

Surgilūm is an ophthalmic surgical device company dedicated to bringing innovative instruments to surgeons, improving surgery by enhancing surgical visualization through first in class, ergonomic and beautiful devices.
Supporter Directory

TARSUS PHARMACEUTICALS, INC.
15440 Laguna Canyon Rd, Ste 160
Irvine, CA 92618
(949) 418-1801
www.tarsusrx.com

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care. The company is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 trials that is being developed for the treatment of Demodex blepharitis. To learn more about Tarsus, Demodex blepharitis, and the company’s pipeline, visit TarsusRx.com.

TEARLAB CORPORATION
940 S Kimball Ave
Southlake, TX 76092
(855) 832-7522
www.tearlab.com

Osmolarity testing empowers clinicians to accurately detect Visually Significant Ocular Disease and is considered an essential test by the ASCRS. Abnormal osmolarity can adversely impact accuracy of refractive measurements. It is an established test, cited in 100+ papers, reimbursed by Medicare and has been trusted in 20M+ eyes globally.

TIFFANY MOON, MD
4347 W. Northwest Hwy
Ste 130 #145
Dallas, TX 75220
(214) 519-8587
www.shop.tiffanymoonmd.com

Tiffany Moon, M.D. is a Board-Certified Anesthesiologist, mother, wife, philanthropist, entrepreneur, and was on season 5 of Real Housewives of Dallas on Bravo TV. She has published more than three dozen original manuscripts, reviews, and book chapters and speaks internationally on topics related to her research. Dr. Moon loves to express her creativity and humor through fashion, her Aroma-Shesia Candle Collection, and her jewelry line. Eternal Love by Tiffany Moon is inspired by Tiffany’s passion for style and the people she loves. The emblem combines O, which represents Eternity, and a heart, which represents Love. As Tiffany always says, “Lead with Love.”

TWENTY/ TWENTY BEAUTY
43 Yawpo Ave, Ste 1
Oakland, NJ 07436
(201) 337-9300

Created by ophthalmologist, Diane Hilal-Campo, MD, twenty / twenty beauty is rooted in science and committed to eye health; our products are ophthalmologist tested and proven to be safe for sensitive eyes and contact lens wearers. Our products are always formulated without toxic ingredients and are vegan, cruelty free, and paraben free. All products are free from glitter, mica, loose mineral powders, prostaglandins, fragrance, argireline, acetyl hexapeptide-3, acetyl hexapeptide-8, and benzalkonium chloride. Clean, high performance formulas. Products are formulated with a hybrid of natural ingredients such as castor oil, argan oil, and vitamin E and other clean cosmeceuticals that work with your skin and eyes to deliver visible, safe and lasting results.
Supporter Directory

UNSGHED HERO
853 N. Orange Dr
Los Angeles, CA 90038
(818) 470-1292
www.unsung-hero.com

Unsung Hero provides the ultimate quality in medical garments & accessories at understandable prices. Our craft is focused on bridging fashion & function for medical professionals. Created by a family of nurses and doctors aspiring to reinvent the traditional uniform.

CARL ZEISS MEDITEC USA, INC.
5500 Central Pkwy
Dublin, CA 94568
(925) 557-4100
www.zeiss.com/med

ZEISS offers complete solutions to diagnose, manage, and treat ophthalmic disease. The comprehensive ZEISS portfolio is designed to meet the demands of eye care professionals in glaucoma, retina, comprehensive, cataract and refractive specialties. With additional solutions in data management, ZEISS products help doctors to deliver the best possible patient care.
INDICATIONS AND USAGE FOR RHOPRESSA® AND ROCKLATAN®

- Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

- Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION FOR RHOPRESSA®

WARNINGS AND PRECAUTIONS

- Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been previously contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

- Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be reinserted 15 minutes following its administration.

IMPORTANT SAFETY INFORMATION FOR ROCKLATAN®

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

- Pigmentation changes
- Eyelash changes
- Intraocular inflammation
- Macular edema
- Herpetic keratitis
- Bacterial keratitis
- Contact lens wear

For more information, please visit www.Rocklatan.com and www.Rhopressa.com

Rhopressa® is a registered trademark of Aerie Pharmaceuticals, Inc. Rocklatan® is a registered trademark of Aerie Pharmaceuticals, Inc. ©2021 Aerie Pharmaceuticals, Inc. All rights reserved. US-RHO-P-0351 07/21
IQ Vivity™ IOL. In addition, patients should be warned that IQ Vivity™ Extended Vision IOLs include AcrySof EMBRACE THE ATTENTION:

the AcrySof provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with reported very bothersome starbursts, halos, blurred vision, or dark area visual disturbances; however, no explants were reported. Prior to surgery, physicians should possible to experience very bothersome visual disturbances, significant enough that the patient could request explant of the IOL. In the AcrySof monofocal IOL, the lens provides improved intermediate and near visual acuity while maintaining comparable distance visual acuity. The AcrySof IQ Vivity™ IOL is intended for capsular bag placement only. In addition, the AcrySof IQ Vivity™ Toric IOL is indicated for the reduction of residual refractive astigmatism in adult patients with pre-existing corneal astigmatism.

WARNING/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. This lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary, lens repositioning should occur as early as possible prior to lens encapsulation. Most patients implanted with the AcrySof IQ Vivity™ IOL are likely to experience significant loss of contrast sensitivity as compared to a monofocal IOL. Therefore, it is essential that prospective patients be fully informed of this risk before giving their consent for implantation of the AcrySof IQ Vivity™ IOL. In addition, patients should be warned that they will need to exercise caution when engaging in activities that require good vision in dimly lit environments, such as driving at night or in poor visibility conditions, especially in the presence of oncoming traffic. It is possible to experience very bothersome visual disturbances, significant enough that the patient could request explant of the IOL. In the AcrySof IQ Vivity™ IOL clinical study, 1% to 2% of AcrySof IQ Vivity™ IOL patients reported very bothersome starbursts, halos, blurred vision, or dark area visual disturbances; however, no explants were reported. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with the AcrySof IQ Vivity™ IOLs.

ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings, and precautions.

Learn more about the AcrySof® IQ Vivity™ IOL today at: VivityView.com.
INDICATIONS AND USAGE
DURYSTA™ (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION
Contraindications
DURYSTA™ is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’ Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product.

Warnings and Precautions
The presence of DURYSTA™ implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA™ should be limited to a single implant per eye without retreatment. Caution should be used when prescribing DURYSTA™ in patients with limited corneal endothelial cell reserve.

DURYSTA™ should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA™ intracameral implant. DURYSTA™ should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Prostaglandin analogs, including DURYSTA™, have been reported to cause intraocular inflammation. DURYSTA™ should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Ophthalmic bimatoprost, including DURYSTA™ intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA™ can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA™, and patients should be monitored following the administration.

Adverse Reactions
In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache.

Please see Brief Summary of full Prescribing Information on the following page.

Brief Summary—Please see the DURYSTA™ package insert for full Prescribing Information

INDICATIONS AND USAGE
DURYSTA™ is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

CONTRAINDICATIONS
DURYSTA™ is contraindicated in patients with active or suspected ocular or periocular infections; corneal endothelial cell dystrophy; prior corneal transplantation, or endothelial cell transplants; absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; or hypersensitivity to bimatoprost or any other components of the product.

WARNINGS AND PRECAUTIONS

Corneal Adverse Reactions: The presence of DURYSTA™ implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA™ should be limited to a single implant per eye without retraitment. Caution should be used when prescribing DURYSTA™ in patients with limited corneal endothelial cell reserve.

Iridocorneal Angle: Following administration with DURYSTA™, the intracameral implant is intended to settle within the inferior angle. DURYSTA™ should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Macular Edema: Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA™ intracameral implant. DURYSTA™ should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Intraocular Inflammation: Prostaglandin analogs, including DURYSTA™, have been reported to cause intraocular inflammation. DURYSTA™ should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Pigmentation: Ophthalmic bimatoprost, including DURYSTA™ intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. While treatment with DURYSTA™ can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Endophthalmitis: Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA™, and patients should be monitored following the administration.

ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common ocular adverse reaction observed in two randomized, active-controlled clinical trials with DURYSTA™ in patients with OAG or OHT was conjunctival hyperemia, which was reported in 27% of patients. Other common ocular adverse reactions reported in 5-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increase, corneal endothelial cell loss, vision blurred, and iritis. Ocular adverse reactions occurring in 1-5% of patients were anterior chamber cell, lacrimation increased, corneal edema, aqueous humor leakage, iris adhesions, ocular discomfort, corneal touch, iris hyperpigmentation, anterior chamber flare, anterior chamber inflammation, and macular edema.

The following additional adverse drug reactions occurred in less than 1% of patients: hyphema, iridocyclitis, uveitis, corneal opacity, product administered at inappropriate site, corneal decompensation, cystoid macular edema, and drug hypersensitivity.

The most common nonocular adverse reaction was headache, which was observed in 5% of patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no adequate and well-controlled studies of DURYSTA™ administration in pregnant women to inform a drug associated risk. Oral administration of bimatoprost to pregnant rats and mice throughout organogenesis did not produce adverse maternal or fetal effects at clinically relevant exposures. Oral administration of bimatoprost to rats from the start of organogenesis to the end of lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant exposures.

In embryo/fetal developmental studies in pregnant mice and rats, abortion was observed at oral doses of bimatoprost which achieved at least 1770 times the maximum human bimatoprost exposure following a single administration of DURYSTA™ (based on plasma Cmax levels; blood-to-plasma partition ratio of 0.858). In a pre/postnatal development study, oral administration of bimatoprost to pregnant rats from gestation day 7 through lactation resulted in reduced gestation length, increased late resorptions, fetal deaths, and postnatal pup mortality, and reduced pup body weight at 0.3 mg/kg/day (estimated 470-times the human systemic exposure to bimatoprost from DURYSTA™; based plasma Cmax and a blood-to-plasma partition ratio of 0.858). No adverse effects were observed in rat offspring at 0.1 mg/kg/day (estimated 350-times the human systemic exposure to bimatoprost from DURYSTA™; based on plasma Cmax).

Lactation: There is no information regarding the presence of bimatoprost in human milk, the effects on the breastfed infants, or the effects on milk production. In animal studies, topical bimatoprost has been shown to be excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when DURYSTA™ is administered to a nursing woman.

The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for DURYSTA™ and any potential adverse effects on the breastfed child from DURYSTA™.

Pediatric Use: Safety and effectiveness of DURYSTA™ in pediatric patients have not been established.

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

Bimatoprost was not carcinogenic in either mice or rats when administered by oral gavage at doses up to 2 mg/kg/day and 1 mg/kg/day respectively for 104 weeks (approximately 3100 and 1700 times, respectively, the maximum human exposure [based on plasma Cmax levels; blood-to-plasma partition ratio of 0.858]).

Bimatoprost was not mutagenic or clastogenic in the Ames test, in the mouse lymphoma test, or in the in vivo mouse micronucleus tests.

Bimatoprost did not impair fertility in male or female rats up to doses of 0.6 mg/kg/day (1770-times the maximum human exposure, based on plasma Cmax levels; blood-to-plasma partition ratio of 0.858).

PATIENT COUNSELING INFORMATION

Treatment-related Effects: Advise patients about the potential risk for complications including, but not limited to, the development of corneal adverse events, intraocular inflammation or endophthalmitis.

Potential for Pigmentation: Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent.

When to Seek Physician Advice: Advise patients that if the eye becomes red, sensitive to light, painful, or develops a change in vision, they should seek immediate care from an ophthalmologist.

Rx only
**INDICATION**

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

**IMPORTANT SAFETY INFORMATION**

- Increased pigmentation of the iris and periocular tissue (eyelid) can occur. Iris pigmentation is likely to be permanent.
- Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation.
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation.
- Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
- There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients.
- Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration.
- Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%).

For more information, please see Brief Summary of full Prescribing Information on adjacent page.

**References:**
1. VYZULTA Prescribing Information. Bausch & Lomb Incorporated.
2. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus twice-daily timolol maleate 0.5% in patients with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965-973.
Pigmentation is expected to increase as long as latanoprostene bunod ophthalmic solution pigmented tissues. The most frequently reported changes with prostaglandin analogs VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% may cause changes to 5.1 Pigmentation

5 WARNINGS AND PRECAUTIONS

5.1 Pigmentation

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% may cause changes to pigmented tissues. The most frequently reported changes with prostaglandin analogs VYZULTA, pigmentation of the iris is likely to be permanent, while pigmentation of the arch vessels, domed head, sternebral and vertebral skeletal anomalies, limb hyperextension and malrotation, abdominal distension and edema. Latanoprostene bunod was not teratogenic in the rat when administered (IV) at 150 mcg/kg/day (87 times the clinical dose) [see Data]. The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.

8.2 Lactation

Use in pediatric patients aged 16 years and younger is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Latanoprostene bunod was not mutagenic in bacteria and did not induce micronuclei formation in the in vivo rat bone marrow micronucleus assay. Chromosomal aberrations were observed in vitro with human lymphocytes in the absence of metabolic activation. Latanoprostene bunod has not been tested for carcinogenic activity in long-term animal studies. Latanoprostene bunod is a main metabolite of latanoprostene bunod. Exposure of rats and mice to latanoprost, resulting from oral dosing with latanoprost in lifetime rodent bioassays, was not carcinogenic.


6.6 REACTIVE ADVERSE EVENTS

The following adverse reactions are described in the Warnings and Precautions section: pigmentation (5.1), eyelash changes (5.2), intraocular inflammation (5.3), macular edema (5.4), bacterial keratitis (5.5), use with contact lens (5.6).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of another drug may not be directly compared to rates in the clinical trials of latanoprostene bunod. Data from these adverse reactions and metastatic neoplasms were produced at doses of 300 mcg/kg/day (174 times the clinical dose). Malformations included anomalies of the sternum, domed head, forepaw hyperextension and hindlimb malrotation, vertebral anomalies and delayed ossification of distal limb bones. A no observed adverse effect level (NOAEL) was established at 150 mcg/kg/day (87 times the clinical dose) in this study.

8.4 Pediatric Use

Use in pediatric patients aged 16 years and younger is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

13.2 Animal Toxicology and/or Pharmacology

A 9-month toxicity study administered topical ocular doses of latanoprostene bunod to one eye of cynomolgus monkeys; control (vehicle only), one drop of 0.024% bid, one drop of 0.04% bid and two drops of 0.04% per dose, bid. The systemic exposures are equivalent to 4.2-fold, 7.9-fold, and 13.5-fold the clinical dose, respectively, on a body surface area basis (assuming 100% absorption). Microscopic evaluation of the lungs after 9 months observed pleural/subpleural chronic fibrosis/inflammation in the 0.04% dose male groups, with increasing incidence and severity compared to controls. Lung toxicity was observed at 0.024% dose. U.S. Patent Numbers: 7,273,946; 7,629,345; 7,910,767; 8,058,467.

VYZULTA is a trademark of Bausch & Lomb Incorporated or its affiliates. © 2020 Bausch & Lomb Incorporated or its affiliates.

Distributed by:

Bausch + Lomb, a division of Bausch Health US, LLC

Bridgewater, NJ 08807 USA

Based on 9612403 (Folded), 9612303 (Flat) 5/2019

VYZ.0109USA.20 issued: 5/2020


6.6 REACTIVE ADVERSE EVENTS

The following adverse reactions are described in the Warnings and Precautions section: pigmentation (5.1), eyelash changes (5.2), intraocular inflammation (5.3), macular edema (5.4), bacterial keratitis (5.5), use with contact lens (5.6).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of another drug may not be directly compared to rates in the clinical trials of latanoprostene bunod. Data from these adverse reactions and metastatic neoplasms were produced at doses of 300 mcg/kg/day (174 times the clinical dose). Malformations included anomalies of the sternum, domed head, forepaw hyperextension and hindlimb malrotation, vertebral anomalies and delayed ossification of distal limb bones. A no observed adverse effect level (NOAEL) was established at 150 mcg/kg/day (87 times the clinical dose) in this study.

8.4 Pediatric Use

Use in pediatric patients aged 16 years and younger is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.

13.2 Animal Toxicology and/or Pharmacology

A 9-month toxicity study administered topical ocular doses of latanoprostene bunod to one eye of cynomolgus monkeys; control (vehicle only), one drop of 0.024% bid, one drop of 0.04% bid and two drops of 0.04% per dose, bid. The systemic exposures are equivalent to 4.2-fold, 7.9-fold, and 13.5-fold the clinical dose, respectively, on a body surface area basis (assuming 100% absorption). Microscopic evaluation of the lungs after 9 months observed pleural/subpleural chronic fibrosis/inflammation in the 0.04% dose male groups, with increasing incidence and severity compared to controls. Lung toxicity was observed at 0.024% dose. U.S. Patent Numbers: 7,273,946; 7,629,345; 7,910,767; 8,058,467.

VYZULTA is a trademark of Bausch & Lomb Incorporated or its affiliates. © 2020 Bausch & Lomb Incorporated or its affiliates.

Distributed by:

Bausch + Lomb, a division of Bausch Health US, LLC

Bridgewater, NJ 08807 USA

Based on 9612403 (Folded), 9612303 (Flat) 5/2019

VYZ.0109USA.20 issued: 5/2020
Neurotrophic keratitis is a degenerative disease that warrants immediate treatment.

OXERVATE is the first FDA-approved pharmacologic treatment that targets the root pathogenesis of neurotrophic keratitis (NK).

In clinical studies, with a single 8-week course of therapy:
- Up to 72% of patients with NK achieved complete corneal healing.
- 80% of patients who achieved complete corneal healing remained completely healed at 1 year.

Cenegermin-bkbj, the active ingredient in FDA-approved OXERVATE, is structurally identical to the human nerve growth factor (NGF) protein made in ocular tissues.

Endogenous NGF is a protein involved in the differentiation and maintenance of neurons and is believed to support corneal integrity through three mechanisms: corneal innervation, tear secretion, and epithelial cell growth.

Indication
OXERVATE is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis.

Important Safety Information
WARNINGS AND PRECAUTIONS
Patients should remove contact lenses before applying OXERVATE and wait 15 minutes after instillation of the dose before reinsertion.

ADVERSE REACTIONS
The most common adverse reaction in clinical trials that occurred more frequently with OXERVATE was eye pain (16% of patients).

Other adverse reactions included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, and increase in tears (1%-10% of patients).

Please see additional Important Safety Information on accompanying page and full Prescribing Information, including patient information, at OXERVATE.com/prescribing-information.

References:
Brief Summary of Safety
Consult the full Prescribing Information for complete product information.

INDICATIONS AND USAGE
OXERVATE™ (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.

DOSEAGE AND ADMINISTRATION
Contact lenses should be removed before applying OXERVATE and may be reinserted 15 minutes after administration.
If a dose is missed, treatment should be continued as normal, at the next scheduled administration.
If more than one topical ophthalmic product is being used, administer the eye drops at least 15 minutes apart to avoid diluting products. Administer OXERVATE 15 minutes prior to using any eye ointment, gel or other viscous eye drops.

Recommended Dosage and Dose Administration
Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks.

ADVERSE REACTIONS
Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In two clinical trials of patients with neurotrophic keratitis, a total of 101 patients received cenegermin-bkbj eye drops at 20 mcg/mL at a frequency of 6 times daily in the affected eye(s) for a duration of 8 weeks. The mean age of the population was 61 to 65 years of age (18 to 95). The majority of the treated patients were female (61%). The most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Other adverse reactions occurring in 1-10% of OXERVATE patients and more frequently than in the vehicle-treated patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation and tearing.

USE IN SPECIFIC POPULATIONS
Pregnancy
Risk Summary There are no data from the use of OXERVATE in pregnant women to inform any drug associated risks.
Administration of cenegermin-bkbj to pregnant rats or rabbits during the period of organogenesis did not produce adverse fetal effects at clinically relevant doses. In a pre- and postnatal development study, administration of cenegermin-bkbj to pregnant rats throughout gestation and lactation did not produce adverse effects in offspring at clinically relevant doses.
Animal Data
In embryofetal development studies, daily subcutaneous administration of cenegermin-bkbj to pregnant rats and rabbits throughout the period of organogenesis produced a slight increase in post-implantation loss at doses greater than or equal to 42 mcg/kg/day (267 times the MRHOD). A no observed adverse effect level (NOAEL) was not established for post-implantation loss in either species.

In rats, hydrocephaly and urogenital anomalies were each observed in one fetus at 267 mcg/kg/day (1709 times the MRHOD). In rabbits, cardiovascular malformations, including ventricular and atrial septal defects, enlarged heart and aortic arch dilation were each observed in one fetus at 83 mcg/kg/day (534 times the MRHOD). No fetal malformations were observed in rats and rabbits at doses of 133 mcg/kg/day and 42 mcg/kg/day, respectively. In a pre- and postnatal development study, daily subcutaneous administration of cenegermin-bkbj to pregnant rats during the period of organogenesis and lactation did not affect parturition and was not associated with adverse toxicity in offspring at doses up to 267 mcg/kg/day. In parental rats and rabbits, an immunogenic response to cenegermin-bkbj was observed. Given that cenegermin-bkbj is a heterologous protein in animals, this response may not be relevant to humans.

Lactation
There are no data on the presence of OXERVATE in human milk, the effects on breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for OXERVATE, and any potential adverse effects on the breastfed infant from OXERVATE.

Pediatric Use
The safety and effectiveness of OXERVATE have been established in the pediatric population. Use of OXERVATE in this population is supported by evidence from adequate and well-controlled trials of OXERVATE in adults with additional safety data in pediatric patients from 2 years of age and older [see Clinical Studies (14)].

Geriatric Use
Of the total number of subjects in clinical studies of OXERVATE, 43.5% were 65 years old and over. No overall differences in safety or effectiveness were observed between elderly and younger adult patients.

NONCLINICAL TOXICOLOGY
Carcinogenesis and Mutagenesis Animal studies have not been conducted to determine the carcinogenic and mutagenic potential of cenegermin-bkbj.

Impairment of fertility Daily subcutaneous administration of cenegermin-bkbj to male and female rats for at least 14 days prior to mating, and at least 18 days post-coitum had no effect on fertility parameters in male or female rats at doses up to 267 mcg/kg/day (1709 times the MRHOD). In general toxicology studies, subcutaneous and ocular administration of cenegermin-bkbj in females was associated with ovarian findings including persistent estrus, ovarian follicular cysts, atrophy/reduction of corpora lutea, and changes in ovarian weight at doses greater than or equal to 19 mcg/kg/day (119 times the MRHOD).

© 2019 Dompé U.S. Inc. All rights reserved. US-OXE-1900010 06/19
TECNIS Synergy™ IOL

A Breakthrough Innovation

Going beyond the limits of current trifocals.

* Widest* range of continuous vision**
with best near**

* Superior image contrast†
and night, delivering vision
that patients can trust³

* Excellent patient outcomes
so they can enjoy the moments
that matter most†⁶

** vs. AcrySof® IQ PanOptix®, TECNIS Symfony™, TECNIS® Multifocal. Based on comparison of DFU defocus curves and head to head clinical study vs. PanOptix®.

† Continuous 20/32 or better

† vs. PanOptix® IOL

† Based on interim 6-months post-operative data

INDICATIONS and IMPORTANT SAFETY INFORMATION FOR TECNIS Synergy™ IOL with TECNIS Simplicity® Delivery System, Model DFR00V and TECNIS Synergy™ Toric II IOL with TECNIS Simplicity® Delivery System, Models DFW150, DFW225, DFW300, DFW375

Rx Only

INDICATIONS: The TECNIS Simplicity® Delivery System is used to fold and assist in inserting the TECNIS Synergy™ IOL which is indicated for primary implantation for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The TECNIS Simplicity® Delivery System is used to fold and assist in inserting the TECNIS Synergy™ Toric II IOLs that are indicated for primary implantation for the visual correction of aphakia and for reduction of refractive astigmatism in adult patients with greater than or equal to 1 diopter of preoperative corneal astigmatism, in whom a cataractous lens has been removed. Compared to an aspheric monofocal lens, the TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing improved visual acuity at intermediate and near distances to reduce eyeglass wear, while maintaining comparable distance visual acuity. The lens is intended for capsular bag placement only.

WARNINGS: Intraocular lenses may exacerbate an existing condition, may interfere with diagnosis or treatment of a condition or may pose an unreasonable risk to the eyesight of patients. Patients should have well-defined visual needs and be informed of possible visual effects (such as a perception of halo, starburst or glare around lights), which may be expected in nighttime or poor visibility conditions. Patients may perceive these visual effects as bothersome, which, on rare occasions, may be significant enough for the patient to request removal of the IOL. The physician should carefully weigh the potential risks and benefits for each patient. Patients with a predicted postoperative residual astigmatism greater than 1.0 diopter, with or without a toric lens, may not fully benefit in terms of reducing spectacle wear. Rotation of the TECNIS Synergy™ Toric II IOL from its intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, lens repositioning should occur as early as possible, prior to lens encapsulation. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. Not doing so may result in the lens being stuck in the cartridge. Do not attempt to disassemble, modify, or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. PRECAUTIONS: Interpret results with caution when using autorefract or wavefront aberrometers that utilize infrared light, or when performing a diocthrome test. Confirmation of refraction with maximum plus manifest refraction technique is strongly recommended. The ability to perform some eye treatments (e.g., retinal photocoagulation) may be affected by the IOL optical design. The surgeon should target emmetropia, as this lens is designed for optimum visual performance when emmetropia is achieved. The TECNIS Synergy™ IOLs should not be placed in the ciliary sulcus. Carefully remove all viscoelastic and do not over-inflate the capsular bag at the end of the case. Residual viscoelastic and/or over-inflation of the capsular bag may allow the lens to rotate, causing misalignment of the TECNIS Synergy™ Toric II IOL. All preoperative surgical parameters are important when choosing a TECNIS Synergy™ Toric II IOL for implantation, including preoperative kerometric cylinder (magnitude and axis), incision location, the surgeon’s estimated surgically induced astigmatism (SIA) and biometry. Variability in any of the preoperative measurements can influence patient outcomes and the effectiveness of treating eyes with lower amounts of preoperative corneal astigmatism. The effectiveness of TECNIS Synergy™ Toric II IOLs in reducing postoperative residual astigmatism in patients with preoperative corneal astigmatism < 1.0 diopter has not been demonstrated. Patients with a predicted postoperative astigmatism greater than 1.0 D may not be suitable candidates for implantation with the TECNIS Synergy™ and TECNIS Synergy™ Toric II IOLs, as they may not obtain the benefits of reduced spectacle wear or improved intermediate and near vision seen in patients with lower predicted postoperative astigmatism. ATTENTION: Reference the Directions for Use for a complete listing of Indications and Important Safety Information.

© Johnson & Johnson Surgical Vision, Inc. 2021 PP2021CT4961
At Novartis, we harness the innovating power of science to address some of society’s most challenging health care issues. We are passionate about discovering new ways to improve and extend people’s lives.
WE’LL KEEP THE DOSE ON

Dextenza®
(dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use

A DOSE OF CONFIDENCE GOES A LONG WAY.
Once you’re back to caring for patients, they’ll appreciate that one DEXTENZA insert gives them their post-op ophthalmic steroid dose, completely hands-free.¹,²

DEXTENZA is designed to:
• Allow for physician-controlled administration¹
• Provide preservative-free, sustained coverage for up to 30 days²

INDICATION
DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, fungal diseases of the eye, and dacryocystitis.

WARNINGS AND PRECAUTIONS
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

ADVERSE REACTIONS
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%).

The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%).

Please see brief summary of full Prescribing Information on adjacent page.


© 2021 Ocular Therapeutix, Inc. All rights reserved. DEXTENZA is a registered trademark of Ocular Therapeutix, Inc. PP-US-DX-0230

________________________________________

WIO Awards Ceremony & Networking Reception @ AAO
Saturday 11.13.21
5:30-7:30 pm

"Fais do-do"
9 years of extensive real-world and clinical experience, backed by 8 phase 3 clinical trials¹

>13 million doses administered to hundreds of thousands of patients²

82% of payers offer access to EYLEA first line, covering >272 million patients²звездка

EYLEA4U® provided

>4.4 million support services to eligible patients as of June 30, 2020²

*Data represent payers across the following channels: Medicare Part B, Commercial, Medicare Advantage, and VA. Individual patient coverage is subject to patient’s specific plan.

GO TO HCP.EYLEA.US TO LEARN MORE


EYLEA and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

REGENERON
© 2021, Regeneron Pharmaceuticals, Inc. All rights reserved. 777 Old Saw Mill River Road, Tarrytown, NY 10591

03/2021
EYL.21.02.0035
Save the date!

WIO 2022
Summer Symposium
August 25–28
Portola Hotel & Spa · Monterey, California

www.wioonline.org
We want to hear from you.
Do you have suggestions for next year’s Summer Symposium?
Email us at info@wioonline.org.